- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00893347
An Intervention Program to Reduce to the Risk of Persistent Symptoms After Concussion
Prevention of Persistent Post-concussion Syndrome With Cognitive-behavioural Therapy in At-risk Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although the majority of patients with mild traumatic brain injury (MTBI) experience complete recovery within three months, a sizeable group continues to report frequent and severe symptoms such as headaches, fatigue, difficulty concentrating, forgetfulness, and irritability, in what is labeled persistent post-concussion syndrome (PCS). Persistent PCS is associated with vocational, recreational, and social disability. Early education and reassurance (treatment as usual) is effective in general, but appears insufficient for this subgroup.
Recent research has identified risk factors for persistent PCS, including inaccurate illness beliefs, maladaptive coping behaviour, and emotional distress. The present study will evaluate the additive efficacy of a cognitive-behavioural therapy protocol designed to modify these risk factors, over and above treatment as usual.
Participants with MTBI will be recruited within six weeks of injury. Those identified as being at-risk for persistent PCS based on evidence-based criteria will receive treatment as usual and then be randomly assigned to receive either no further intervention or cognitive-behavioural therapy. We hypothesize that the group receiving cognitive-behavioural therapy will have fewer PCS symptoms and be less disabled at follow-up. We also hypothesize that compensation-seeking status will mitigate this improvement and that illness beliefs, coping behaviour, and emotional distress will mediate this improvement. A blinded rater will conduct the baseline and outcome assessments.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- GF Strong Rehab Centre, 4255 Laurel Street
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Incurred head trauma within six weeks of study entry
- Meet American Congress of Rehabilitation criteria for MTBI, documented by the referring/treating physician
- Subjective report at least one symptom attributable to head trauma
- English as preferred language for communication
- Considered at-risk for persistent PCS based on prognostic model from Whittaker et al. (2007)
Exclusion Criteria:
- Medical documentation of skull fracture or acute intracranial abnormality on neuroimaging, consistent with "mild-complicated" TBI
- Self-reported history of a neurological disorder (including prior MTBI within the past six months)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: I
Treatment as usual
|
Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
|
|
Experimental: II
Treatment as usual + cognitive-behavioural therapy
|
Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PCS symptoms (Rivermead Postconcussion Symptoms Questionnaire)
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
|
Functional disability (Mayo-Portland Participation Index)
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Illness beliefs (Illness Perceptions Questionnaire-Revised)
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
|
Coping style (PCS Coping Inventory)
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
|
Psychological distress (Hospital Anxiety and Depression Scale) )
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
|
Pain (Brief Pain Scale)
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
|
Psychiatric diagnosis (MINI International Neuropsychiatric Interview)
Time Frame: Pre-intervention and three months later
|
Pre-intervention and three months later
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Noah Silverberg, PhD, University of British Columbia
- Study Director: Brad Hallam, University of British Columbia
- Study Director: Alice Rose, Vancouver Coastal Health
- Study Director: Heather Underwood, University of British Columbia
- Study Director: Allen Thornton, Simon Fraser University
- Study Director: Kevin Whitfield, Simon Fraser University
- Study Director: Maureen Whittal, University of British Columbia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H08-02595
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Traumatic Brain Injury
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
Oragenics, Inc.Not yet recruitingMild Traumatic Brain Injury, ConcussionAustralia
-
Michael HarlEnrolling by invitationBrain Injury | Concussion | Mild Traumatic Brain Injury (mTBI)United States
-
McGill University Health Centre/Research Institute...UnknownMild Traumatic Brain Injury; ConcussionCanada, France, Israel
-
ElMindA LtdGE HealthcareCompletedTBI (Traumatic Brain Injury) | Mild Traumatic Brain Injury | Concussion, MildUnited States
-
Henry M. Jackson Foundation for the Advancement...Brooke Army Medical Center; Tripler Army Medical CenterRecruitingMild Traumatic Brain Injury (mTBI)United States
-
Washington University School of MedicineTerminated
-
First Affiliated Hospital Xi'an Jiaotong UniversityHealth Science Center of Xi'an Jiaotong University; The Second Affiliated Hospital...RecruitingMTBI - Mild Traumatic Brain InjuryChina
-
Perception Dynamics InstituteUniversity of California, San Diego; University of South Alabama; University...Active, not recruitingMTBI - Mild Traumatic Brain InjuryUnited States
-
Centre Hospitalier de DouaiCompletedCompliance, Patient | Mild Brain Traumatic InjuryFrance
Clinical Trials on Treatment as usual
-
Universitätsklinikum Hamburg-EppendorfCompletedPerioperative AnxietyGermany
-
University of ChicagoNational Institute of Mental Health (NIMH)Not yet recruitingHIV | Financial Stress
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
University Hospital, AkershusUniversity of OsloActive, not recruiting
-
McMaster UniversityNot yet recruiting
-
Gaia AGWithdrawnType 2 DiabetesGermany
-
Centre for Addiction and Mental HealthCompleted
-
King's College LondonUnknown
-
Universitat Jaume IConsorcio Hospitalario Provincial de CastellónCompletedDepression | AnxietySpain
-
University of IndianapolisUniversity of Missouri, Kansas City; Missouri State UniversityCompletedHypertension | Diabete Type 2United States